# STAMPEDE 2 (NCT06320067)

> A Randomised Controlled Platform Trial Testing Treatments in Metastatic Hormone Sensitive Prostate Cancer

No report yet. It can be ordered.

## Registry

- Registry record: https://clinicaltrials.gov/study/NCT06320067
- Phase: PHASE3
- Status: RECRUITING
- Sponsor: University College, London
- Conditions: Prostate Cancer Metastatic
- Interventions: Stereotactic Ablative Body Radiotherapy (SABR); 177Lu-PSMA-617; Androgen Deprivation Therapy (ADT); Androgen Receptor Signalling Inhibitor (ARPI); Radiotherapy to Prostate ± Pelvic Nodes; Docetaxel
- Enrollment: 3360
- Primary outcome: Overall Survival (OS)

## Preliminary discovery

Commentary in our index that names this trial so far. Final coverage is set when the report is built.

- X threads: 38
- Podcasts: 22
- YouTube: 9

## Order

Deep, $1,950, price fixed at order: https://www.erudio.com/contact?report=stampede-2-nct06320067

## Free preview

POST https://www.erudio.com/api/trial-requests with {"nct_id": "NCT06320067", "email": "<work email>"}; the inbox owner confirms by the emailed link.